Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sueh-Li Lim, Bradley Augustson, Hira S Mian, Edward A. Stadtmauer, Shinsuke Iida, Michael Slade, Saswati Hazra, Kamal Chamoun, Patricia Cheung, Jamal Saeh, Nina Shah, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 2000.2.

https://doi.org/10.1182/blood-2024-207816

Published: 2024

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Journal Articles

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Zainul S. Hasanali, Alfred L. Garfall, Dan T. Vogl, Sandra Susanibar-Adaniya, Adam D. Cohen, Edward A. Stadtmauer, Shivani Kapur, Adam Waxman, David Allman

Blood (2024) 144 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2024-209100

Published: 2024

Journal Articles

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Adam D. Cohen, Sandra Susanibar-Adaniya, Oksana De Mesa, Alfred L. Garfall, Dan T. Vogl, Adam Waxman, Shivani Kapur, E Paul Wileyto, Anjana Nair, Zainul S. Hasanali, Lauren Karpf, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2024-203635

Published: 2024

Journal Articles

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Chau Nguyen, Cynthia Diaczynsky, Inna Strakovsky, Eva Bondesson, Helen Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra Susanibar-Adaniya, Adam Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 7060.

https://doi.org/10.1182/blood-2024-204155

Published: 2024

Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Blood (2024) 144 (Supplement 1): 3381.1.

https://doi.org/10.1182/blood-2024-199411

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini

Blood (2024) 144 (Supplement 1): 81.

https://doi.org/10.1182/blood-2024-199615

Published: 2024

Journal Articles

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

Margaret Stalker, Alfred L. Garfall, Adam D. Cohen, Dan T. Vogl, Sandra Susanibar-Adaniya, Mia Djulbegovic, Edward A. Stadtmauer, Oxana Megherea, Adam Waxman

Blood (2023) 142 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2023-189277

Published: 2023

Journal Articles

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Mia Djulbegovic, Meredith Doherty, Katie Fanslau, Kan Chen, Sarah Girgis, Pearl Joslyn, Shawn Carney, Joyce Mitchell, Abbie Etzweiler, Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam Waxman, Sandra Susanibar-Adaniya, Zachary AK Frosch, Qi Long, Karen Glanz, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 909.

https://doi.org/10.1182/blood-2023-174451

Published: 2023

Journal Articles

Real-Word Analysis of Clinical Characteristics and Outcomes Among Elderly Patients (pts) with Multiple Myeloma (MM)

Xinhe Shan, Edward A. Stadtmauer, Sandra Susanibar-Adaniya

Blood (2023) 142 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2023-174314

Published: 2023

Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2023-187409

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Beatrice Razzo, Connor Grady, Sandra Susanibar-Adaniya, Adam Waxman, Dan T. Vogl, Adam D. Cohen, Edward A. Stadtmauer, Wei-Ting Hwang, Alfred L. Garfall

Blood (2023) 142 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2023-177735

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Edward A. Stadtmauer, Omar Elghawy, Todd F. Roberts, Deepu Madduri, Sikander Ailawadhi, Mike Royal, Ying Yan

Blood (2023) 142 (Supplement 1): 6851.

https://doi.org/10.1182/blood-2023-178636

Published: 2023

Journal Articles

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer

Blood (2022) 140 (Supplement 1): 12628–12629.

https://doi.org/10.1182/blood-2022-165526

Published: 2022

Journal Articles

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D Cohen

Blood (2022) 140 (Supplement 1): 10081–10083.

https://doi.org/10.1182/blood-2022-165650

Published: 2022

Journal Articles

The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development

Zainul Hasanali, Alfred L. Garfall, Martin P. Carroll, Anthony Secreto, Nicolas Skuli, Carly Roman, Leonard Shultz, Neil Sheppard, Edward A. Stadtmauer, David Allman

Blood (2022) 140 (Supplement 1): 9921–9922.

https://doi.org/10.1182/blood-2022-167751

Published: 2022

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

NARROW

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series

A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma

Real-Word Analysis of Clinical Characteristics and Outcomes Among Elderly Patients (pts) with Multiple Myeloma (MM)

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only